Modern al(radio)chemistry to diagnose and treat cancer
Feb 2, 2024
2:30PM to 3:30PM
Date/Time
Date(s) - 02/02/2024
2:30 pm - 3:30 pm
Categories
Dr. Valery Radchenko
Research Scientist at TRIUMF
Adjunct professor at the University of British Columbia, Chemistry Department
The use of radionuclides has become more and more common in the diagnosis and therapy of cancer. Targeted radionuclide diagnostics and therapy based on the combination of appropriate radionuclides with selective delivery systems (e.g. antibodies, peptides etc.) maximizes the precision of the imaging as well as minimizes the damage of healthy tissues during therapy. Furthermore, based on imaging (tumor sizes and locations), appropriate therapeutic radionuclides emitting alpha, beta- particles or auger electrons can be utilized. Appropriate bifunctional chelator systems should be in place to effectively attach some of the radionuclides (e.g. radiometals) to biomolecules.
Two main sources are utilized for the production of medical radionuclides including production with protons (cyclotrons) and neutrons (reactors). Alternatively, radionuclide generator systems can be utilized as effective cyclotron/reactor-independent sources of medical radionuclides, where the parent radionuclide is produced by a cyclotron or reactor and then serves as a source of a shorter-lived daughter radionuclide which can be utilized for nuclear medicine purposes. After production, in most cases, medical radionuclides need to be isolated from the target material and preconditioned for further radiopharmaceutical application.
TRIUMF provides a unique infrastructure for the production of medical radionuclides with protons for imaging and therapy. Low energy (TR-13) is a working horse of the Life Sciences Division, which is used for the production of well-established imaging radionuclides e.g. 18F and 11C, as well as several imaging radiometals including but not limited to 68Ga,44Sc, 86Y and 89Zr and few therapeutic radionuclides e.g. 119Sb, 197m+gHg, 103Pd. Besides, TR-13 Life Sciences Division actively utilized several other TRIUMF facilities, including ISAC (production of 209/211At, 225Ra/225Ac, 226Ac, 149/155Tb, 165Er), Isotopes Production Facility (IPF) for spallation reaction on thorium target for production of several emerging therapeutic radionuclides (e.g. 225Ac). The status of utilization of these facilities will be presented as well as potential future production capabilities, including ARIEL proton and electron beamlines and IAMI will be discussed.
Bio:
Dr. Radchenko is Research Scientist at TRIUMF and an adjunct professor at the University of British Columbia, Chemistry Department with the main research focus on the production and application of therapeutic radionuclides for Targeted Radionuclide Therapy (TRT). Radiochemist by training graduated from Saint-Petersburg State Technical University (Russian Federation) in collaboration with the Joint Institute for Nuclear Research (JINR) in Dubna (Russian Federation). He received his Ph.D. from Johannes-Gutenberg University Mainz (Germany) in 2013 with a thesis focused on the design of production of promising radionuclide for immuno-PET: 90Nb. Further, realizing the potential of targeted therapy he pursued a postdoctoral position at Los Alamos National Laboratory, NM, USA, where he worked as a part of the tri-lab effort on the production of 225Ac from spallation of thorium with high-energy protons. Besides, 225Ac production effort, he also worked on other efforts including extraction of valuable medical radionuclides from irradiated thorium targets (e.g. 223/224/225Ra, 230Pa, 103Ru/103mRh, 111Ag), design of production alternative for low energy slot at Isotope Production Facility at LANL and others. He published over 80 scientific papers in peer-reviewed journals and was a guest editor on special issues on alpha and Auger emitters for Targeted Therapy.
In-Person: ABB 102
Online: https://mcmaster.zoom.us/j/93536761372
Meeting ID: 935 3676 1372
Passcode: 010404